Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report January – September 2020

RECOVERY IN THE HOUSING BUSINESSRevenue amounted to SEK 10,858m (11,381), and revenue excluding JM Construction, Business area Construction (under closure), amounted to SEK 10,731m (11,159). Operating profit amounted to SEK 1,239m (1,449)[1)2)]. The operating margin was 11.4 percent (12.7). Operating profit excluding JM Construction, Business area Construction, amounted to SEK 1,263m (1,656) and the operating margin to 11.8 percent (14.8). Profit before tax amounted to SEK 1,185m (1,387). Profit after tax amounted to SEK 932m (1,128). Return on equity for the past twelve months

Chiang Khan and Nan on the list of the “2020 Sustainable Top 100 Destinations”

Thailand’s charming destinations Chiang Khan in Loei and Nan Old City in Nan have been listed among the “2020 Sustainable Top 100 Destinations.” around the world by Green Destinations , a non-profit foundation for sustainable destination development and recognition based in Leiden, The Netherlands.The Sustainable Top 100 competition is organised every year by Green Destinations and partners. Nominations are made based on 30 core sustainability criteria from the Green Destinations Standard (GSTC-Recognised) and a well-written Good Practice Story of destination

Nexam Chemical Holding AB (publ) Interim Report 1 January – 30 September 2020

Strong growth and improved marginThird quarter at a glance Significant events: · Continued profitable growth, +32% compared to the corresponding quarter in 2019. · Continued growth, +89%, for Performance Chemical compared to the corresponding quarter in 2019 · Performance Masterbatch grows with 3% compared to the corresponding quarter in 2019. · Improved margin to 43% compared to 35% to the corresponding quarter in 2019. The improved margin is related to economies of scale in supply chain. · Participation in European development projects for Horizon 2020 and continued

Interim Report January-September 2020

Third quarter · Order intake amounted to SEK 739 (1,238) million, a decline of 40 percent · Net sales increased 19 percent to SEK 1,068 (900) million and 25 percent based on constant exchange rates · EBIT rose 76 percent to SEK 348 (198) million and EBIT margin was 33 (22) percent  · The underlying EBIT was SEK 400 (202) million, an increase of 98 percent. The underlying EBIT margin was 37 (22) percent · Earnings per share were SEK 2.71 (1.52) January-September · Order intake was SEK 2,822 (2,861) million, a decrease of 1 percent · Net sales declined 8 percent to

Sobi publishes report for the third quarter 2020

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the third quarter 2020. Total revenue for the second quarter 2020 was SEK 2,970 M and EBITA was SEK 933 M.  July-September · Total revenue of SEK 2,970 M (2,930), up 1 per cent  (6 per cent at constant exchange rates (CER)) · EBITA[1]  was SEK 933 M (1,099), with an EBITA margin[1] of 31 per cent (38) · Earnings per share before dilution (EPS) of SEK 0.94 (1.84) · Net debt[1] of SEK 12,703 M at 30 September 2020 (15,404 at 31 Dec 2019) · Sales for Elocta® were SEK 1,115 M (

Hansa Biopharma interim report Jan-Sep 2020

Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBMLund October 22, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January – September, 2020. Highlights for the third quarter 2020 · The EU Commission granted conditional approval for Idefirix® (imlifidase) in highly sensitized kidney transplant patients in the European Union. Idefirix is

Munters January-September 2020 interim report - "Strong order intake and profitable growth"

July-September 2020: ·Order intake increased 14%, currency adjusted 21%. The growth was driven by pharma, lithium batteries and services for business area AirTech. Business area FoodTech had strong growth in the swine segment in China. ·Net sales increased 1%, currency adjusted 8%, mainly driven by good growth in business area AirTech’s Data Center US operations and the swine segment in China for business area FoodTech. This was partly offset by a weak development in business area AirTech’s Mist Elimination operations. ·The adjusted EBITA-margin improved 8% to 14.8% (13.

Midsona - Interim Report January-September 2020

Strong free cash flow in a period of challenging market conditionsJuly–September 2020 (third quarter) ● Net sales amounted to SEK 821 million (765). ● EBITDA amounted to SEK 72 million (77) before items affecting comparability, corresponding to a margin of 8.8 percent (10.1). ● Profit for the period was SEK 34 million (35), corresponding to earnings per share of SEK 0.52 (0.77) before dilution and SEK 0.51 (0.77) after dilution. ● Free cash flow amounted to SEK 64 million (19). ● In this somewhat unusual quarter, Midsona was affected more by negative factors attributable to

Peab Quarterly report: Strong cash flow and stable level of orders received

Peab Quarterly report January – September 2020”When we sum up the third quarter Peab’s positive development has clearly continued. The level of orders received has been stable and a strong cash flow has contributed to boosted financial position. The integration of our acquired units is progressing and operations are developing according to plan,” says Jesper Göransson, CEO and President of Peab. Summary according to segment reporting: July – September 2020 · Net sales SEK 14,837 million (13,301), of which acquired operations SEK 2,738 million · Operating profit SEK 844 million

Semcon Interim Report January-September 2020

Improved operating margin and strong cash flowThird quarter  · The operating income amounted to SEK 335 million (410) and the organic growth was -17% · The operating profit amounted to SEK 28 million (32), yielding an operating margin of 8.5% (7.8) · The profit after tax amounted to SEK 21 million (24)  · Earnings per share (EPS) after dilution amounted to SEK 1.21 (1.34)  January-September  · The operating income amounted to SEK 1,226 million (1,369) and the organic growth was -9% · The operating profit before restructuring costs amounted to SEK 118 million (101),

Interim Report January – September 2020

We have greatly increased developing properties for self-management. Value development on investment properties and sales drive the quarter's results.January – September 2020 · Net sales amounted to SEK 1,785 m (395). · The operating profit was SEK 627 m (333), of which SEK 96 m (352) refers to changes in the value of investment properties. · The net profit before tax for the period was SEK 497 m (204) and the profit after tax was SEK 486 m (148). · Earnings per share after deductions for minority shares was SEK 11.91 (3.33). July – September 2020 · Net sales amounted

Rottneros interim report January-September 2020

Production continues to  grow, profit under pressureTHE LIST PRICE for NBSK pulp was 8 % lower in USD and 15 % lower in SEK compared with the third quarter of 2019. Compared with the second quarter  of 2020, the price in SEK decreased by 9 %. NET SALES decreased by 18 % to 508 (617) MSEK in line with falling market prices and slightly lower sales volume. EBIT (operating profit) for the third quarter of 2020 was 4 (54) MSEK. A weak market due to the pandemic affected the result strongly. PROFIT AFTER FINANCIAL ITEMS for the third quarter of 2020 was -1 (49) MSEK. Earnings per  share

Neste's Interim Report for January–September 2020

Neste Corporation, Interim Report, 22 October 2020 at 9 a.m. (EET)Strong performance in Renewable Products – very challenging market in Oil Products continuesThird quarter in brief:  · Comparable operating profit totaled EUR 373 million (EUR 435 million) · Operating profit totaled EUR 425 million (EUR 442 million) · Renewable Products' comparable sales margin, including BTC, was USD 744/ton (USD 722/ton) · Oil Products' total refining margin was USD 5.89/bbl (USD 12.07/bbl) · Cash flow before financing activities was EUR 315 million (EUR 71 million)January-September

Optomed’s board has resolved upon a new option plan

Optomed Plc         Stock Exchange Release    22 October 2020 at 9.00, Helsinki Optomed’s board has resolved upon a new option plan Optomed’s board of directors has resolved upon a new option plan. The resolution is based on the authorization given by the general meeting of 11 June 2020. Option plan 2020A: The total maximum number of options is 150,000 and each option entitled to one share of the company. The options are offered to certain key employees. The purpose of the plan and the basis for the subscription price is the payment of certain incentives that were previously

Outokumpu – Publishing of third-quarter results on November 5, 2020

Outokumpu OyjPress releaseOctober 22, 2020 at 9.00 am EESTOutokumpu – Publishing of third-quarter results on November 5, 2020 Outokumpu will publish its third-quarter results on November 5, 2020 approximately at 12.00 pm EET. Outokumpu’s new strategy will be announced in connection with the third-quarter interim report. On the same day, Outokumpu will arrange a live webcast and a conference call for investors and analysts at 3.00 pm EET (8.00 am US EST, 1.00 pm UK, 2.00 pm CET). The event will be hosted by Outokumpu’s CEO Heikki Malinen and CFO Pia Aaltonen-Forsell. Please

Wallenstam’s Interim report Jan 1–Sep 30, 2020: Wallenstam generates results through its own work

Hans Wallenstam, CEO, and Susann Linde, CFO and Head of Investor Relations, comment on the report at www.wallenstam.se/filmsandpresentations. The film will be released by 08.30 (CEST) at the latest. An audiocast in English with Susann Linde will take place at 09.00 (CEST) at www.financialhearings.com. The presentation is available at www.wallenstam.se/filmsandpresentations before 09.00 (CEST). January 1–September 30, 2020 · The net asset value per share increased by SEK 3.80 during the period and amounted to SEK 95.10 (91.30). · Income from property management amounted to SEK 860

Revenio Group Corporation: Interim report, January 1 - September 30, 2020

Revenio Group Corporation, Stock Exchange Release, October 22, 2020 at 9.00Revenio Group Corporation: Interim report January 1–September 30, 2020 Figures in brackets refer to the same period in the previous year, unless otherwise stated. An excellent quarter driven by strong sales and exceptionally low expenditure July–September 2020 · Net sales totaled EUR 15.8 (14.3) million, a growth of 10.5% · The currency-adjusted growth of net sales in July–September was 17.0%, or 6.4% percentage points stronger than reported · Operating profit was EUR 3.6 million (3.9), a decline

Dates for SSAB’s financial reports in 2021

Dates for SSAB’s financial reports in 2021 and the AGMJanuary 29, 2021                Year-end report for 2020 April 26, 2021                      Q1 – Interim report for January-March 2021 July 21, 2021                       Q2 –Interim report for January-June 2021 October 25, 2021                 Q3 – Interim report for January-September 2021 Reports are published at 7.30am CET/CEST on the release date unless otherwise announced. The Annual Report 2020 will be published no later than week 12. The Annual General Meeting 2021 will be held in Stockholm on April 14, 2021.

ContextVision’s third quarter sees a recovery in sales and market entry in digital pathology is on track

STOCKHOLM – Oct 22, 2020 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its third quarter.    “We are making progress according to plan in digital pathology, and with several completed installations we can now proceed with extended studies in the clinical workflow. The pandemic situation continues to keep business somewhat unpredictable. However, sales in our medical imaging business have increased compared to the second quarter, allowing us to be cautiously optimistic,

UPM and the Guides and Scouts of Finland join forces on topics concerning climate and responsibility

(UPM, Helsinki, 22 October 2020 at 9:00 EET) – UPM and the Guides and Scouts of Finland have initiated a cooperation in order to increase the dialogue and understanding between young people, companies and policy makers especially on topics concerning climate change and responsibility. UPM finds it important to understand the expectations of its stakeholders and to constantly develop its operations increasingly sustainable. "The concern about climate change is growing, especially amongst young people, which is why we want to contribute to the constructive discussions about solutions and

Neste’s Board of Directors decides on payment of second dividend installment

Neste Corporation, Stock Exchange Release, 22 October 2020 at 8.50 a.m. (EET)Neste’s Annual General Meeting (AGM), held on 18 May 2020, made decisions on the company’s dividend distribution and authorized the Board of Directors to decide, in its discretion, on the payment of a second dividend installment in a maximum amount of EUR 0.56 per share, consisting of ordinary dividend of EUR 0.46 per share and extraordinary dividend of EUR 0.10 per share. After having considered the impact of the COVID-19 pandemic on the markets and Neste’s financials, the Board of Directors has today decided

Interim Report for Duni AB (publ) January 1–September 30, 2020

Interim Report for Duni AB (publ) January 1–September 30, 2020July 1–September 30 · Net sales amounted to SEK 1,251 m (1,377), corresponding to a 9.2% decrease in sales. Adjusted for exchange rate movements, net sales decreased by 7.3%. · Earnings per share after dilution amounted to SEK 1.02 (1.71). · Sales recovered after the summer months. · Strong operating income turnaround, from SEK -92 m in Q2 to SEK 110 m in Q3. · Higher capacity utilization and improved contribution margin for fixed costs compared with the second quarter. · Cost-cutting program further

Interim Report January–September 2020

Quarter July–September 2020 · Net sales increased by 7 percent to SEK 1,828 (1,711) million · EBITA* increased by 3 percent to SEK 157 (153) million · Profit after tax increased by 322 million to SEK 97 (-225) million · Earnings per ordinary share increased by SEK 3.0 to SEK 1.00 (-2.00) · An agreement for the sale of Besikta was signed after the end of the quarter. EBITA excluding Besikta increased with 26 percentage  Period January-September 2020 · Net sales increased by 7 percent to SEK 5,376 (5,032) million · EBITA* increased by 25 percent to SEK 400 (319)

Proposed merger with DNB ASA

On 21 October 2020, the Board of Directors of DNB Bank ASA decided, in a board meeting, to call an Extraordinary General Meeting on 30 November 2020 for the consideration of a proposed merger with DNB ASA. DNB ASA announced, on 23 December 2019, that the DNB Group had initiated a merger process between DNB ASA and DNB Bank ASA. On 2 July 2020, it was announced that the Ministry of Finance had given its approval to change the group structure in order for DNB Bank ASA to be the new parent company. The Board of Directors of DNB ASA and DNB Bank ASA have signed a joint merger plan, in

There are no items matching the current filter
There are no more items matching the current filter
Back to top